vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $86.8M, roughly 1.6× IOVANCE BIOTHERAPEUTICS, INC.). On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 46.2%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CTRE vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $86.8M |
| Net Profit | $111.3M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 82.5% | — |
| Revenue YoY | 55.1% | 17.7% |
| Net Profit YoY | 113.5% | — |
| EPS (diluted) | $0.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | $86.8M | ||
| Q3 25 | $132.4M | $67.5M | ||
| Q2 25 | $112.5M | $60.0M | ||
| Q1 25 | $96.6M | $49.3M | ||
| Q4 24 | $86.9M | $73.7M | ||
| Q3 24 | $77.4M | $58.6M | ||
| Q2 24 | $68.9M | $31.1M | ||
| Q1 24 | $63.1M | $715.0K |
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | $-91.3M | ||
| Q2 25 | $68.5M | $-111.7M | ||
| Q1 25 | $65.8M | $-116.2M | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $33.4M | $-83.5M | ||
| Q2 24 | $10.8M | $-97.1M | ||
| Q1 24 | $28.7M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -84.7% | ||
| Q3 25 | 58.1% | -140.7% | ||
| Q2 25 | 61.3% | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | 43.0% | -152.1% | ||
| Q2 24 | 15.1% | -327.6% | ||
| Q1 24 | — | -16464.6% |
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | -135.3% | ||
| Q2 25 | 60.9% | -186.2% | ||
| Q1 25 | 68.1% | -235.5% | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 43.2% | -142.7% | ||
| Q2 24 | 15.6% | -312.2% | ||
| Q1 24 | 45.6% | -15800.8% |
| Q4 25 | $0.52 | — | ||
| Q3 25 | $0.35 | — | ||
| Q2 25 | $0.35 | $-0.33 | ||
| Q1 25 | $0.35 | $-0.36 | ||
| Q4 24 | $0.30 | $-0.24 | ||
| Q3 24 | $0.21 | $-0.28 | ||
| Q2 24 | $0.07 | $-0.34 | ||
| Q1 24 | $0.22 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $297.0M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $698.6M |
| Total Assets | $5.1B | $913.2M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | $297.0M | ||
| Q3 25 | $712.5M | $300.8M | ||
| Q2 25 | $306.1M | $301.2M | ||
| Q1 25 | $26.5M | $359.7M | ||
| Q4 24 | $213.8M | $323.8M | ||
| Q3 24 | $377.1M | $397.5M | ||
| Q2 24 | $495.1M | $412.5M | ||
| Q1 24 | $451.2M | $356.2M |
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
| Q4 25 | $4.0B | $698.6M | ||
| Q3 25 | $4.0B | $702.3M | ||
| Q2 25 | $3.3B | $698.5M | ||
| Q1 25 | $2.9B | $767.9M | ||
| Q4 24 | $2.9B | $710.4M | ||
| Q3 24 | $2.4B | $773.5M | ||
| Q2 24 | $1.9B | $768.5M | ||
| Q1 24 | $1.7B | $680.0M |
| Q4 25 | $5.1B | $913.2M | ||
| Q3 25 | $5.1B | $904.9M | ||
| Q2 25 | $4.7B | $907.4M | ||
| Q1 25 | $3.9B | $966.7M | ||
| Q4 24 | $3.4B | $910.4M | ||
| Q3 24 | $2.9B | $991.1M | ||
| Q2 24 | $2.7B | $964.3M | ||
| Q1 24 | $2.3B | $869.8M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | 3.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | $-52.6M | ||
| Q3 25 | $100.9M | $-78.7M | ||
| Q2 25 | $100.8M | $-67.4M | ||
| Q1 25 | $71.4M | $-103.7M | ||
| Q4 24 | $244.3M | $-73.3M | ||
| Q3 24 | $67.2M | $-59.0M | ||
| Q2 24 | $53.0M | $-98.4M | ||
| Q1 24 | $48.8M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRE
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
